BRANFORD, Conn., Nov. 12, 2010 /PRNewswire/ -- HistoRx, Inc. (privately held), a diagnostics company, announced the launch and first commercial sale this week of clinical diagnostic assays based on AQUA® technology. Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, is launching NexCourse®(1) BCa by AQUA technology, a suite of breast cancer assays based on quantitative immunohistochemistry. NexCourse BCa by AQUA technology is:
- More reproducible than traditional IHC testing, for confidence in determining appropriate therapy
- Minimizes receptor status false-negative results by utilizing an objective, quantified score for protein expression that provides more accurate results; and
- Ideal for confirmatory testing of ER/PR/HER2 status prior to hormonal therapy, antibody-based therapy and/or chemotherapy when initial results are inconclusive or negative.
Genoptix and HistoRx signed a multi-year licensing agreement for AQUA® technology and several diagnostic assays based on it in February 2010; the first commercial use announced today triggers a key milestone payment outlined in the agreement. Genoptix obtained exclusive commercial laboratory rights in the United States to develop and perform estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) assays using HistoRx's proprietary technology. Misclassification of receptor status by IHC is common: several studies have shown that false-positive and false-negative ER/PR/HER2 results occur regularly in laboratories around the country and around the world. Inaccurate results may affect treatment decisions, excluding patients from use of potentially efficacious therapies or inappropriately subjecting patients to therapies known to cause s